Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lintuzumab, an antibody targeting SIGLEC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Erlizumab, an antibody targeting ITGB2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Metelimumab, an antibody targeting TGF-beta1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Matuzumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fontolizumab, an antibody targeting IFNG.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ecromeximab, an antibody targeting GD3 ganglioside.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Aselizumab, an antibody targeting L-Selectin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Talizumab, an antibody targeting IgE.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lumiliximab, an antibody targeting FCER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Galiximab, an antibody targeting B7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cantuzumab, an antibody targeting MUC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Adecatumumab, an antibody targeting EPCAM.